Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Raquel Celis, Bernard Lauwerys et al.|The Lancet|2021Cited by 315
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trialFelice Rivellese, Raquel Celis, Anna E. A. Surace et al.|Nature Medicine|2022Cited by 277
Seronegative autoimmune diseases: A challenging diagnosisMarco Vincenzo Lenti, Antonio Di Sabatino, Carlo Maria Rossi et al.|Autoimmunity Reviews|2022Cited by 87
Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedureCarlo Alberto Scirè, Carlomaurizio Montecucco|Arthritis Research & Therapy|2007Cited by 76
Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic DrugsPaola Secchiero, Francesco Trotta, Federica Corallini et al.|The Journal of Rheumatology|2010Cited by 11